Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mun, Chin Hee | - |
dc.contributor.author | Kim, Jin Ock | - |
dc.contributor.author | Ahn, Sung Soo | - |
dc.contributor.author | Yoon, Taejun | - |
dc.contributor.author | Kim, Su Jeong | - |
dc.contributor.author | Ko, Eunhee | - |
dc.contributor.author | Noh, Hee Dong | - |
dc.contributor.author | Park, Yong Beom | - |
dc.contributor.author | Jung, Hak Jun | - |
dc.contributor.author | Kim, Tae Sung | - |
dc.contributor.author | Lee, Sang Won | - |
dc.contributor.author | Park, Sang Gyu | - |
dc.date.issued | 2019-11-01 | - |
dc.identifier.issn | 1878-5905 | - |
dc.identifier.uri | https://aurora.ajou.ac.kr/handle/2018.oak/30849 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070076960&origin=inward | - |
dc.description.abstract | Aminoacyl-tRNA synthetase (ARS)-interacting multifunctional protein 1 (AIMP1) enhances the expression of proinflammatory cytokines. In our previous study, we have shown that serum AIMP1 in patients with SLE was significantly higher than that of healthy controls. To address whether neutralization of AIMP1 could ameliorate nephritis in lupus-prone mice, we generated atializumab, a humanized antibody against AIMP1 and investigated its therapeutic efficacy. ELISA showed that serum AIMP1 at 23 weeks old was significantly higher than that at 13 weeks old in lupus-prone mice. Therefore, lupus-prone mice were randomly assigned to 5 groups (vehicle, methylprednisolone and 0.5, 2, and 5 mg/kg atializumab). After treatment, disease severity was assessed using a variety of phenotypes, including proteinuria, histological damages, renal deposition of immune-complex. In addition, serum cytokines, anti-dsDNA and IgG subclasses were determined. T cell subsets were analyzed using a fluorescence-activated cell sorter. Atializumab significantly diminished proteinuria, improved glomerular and tubular damages and reduced the renal deposition of immune-complexes. Moreover, atializumab significantly decreased serum interferon (IFN)-γ, interleukin (IL)-17A, and IL-6, whereas it increased serum IL-10. Similarly, atializumab reduced the numbers of TH1, TH2 and TH17 cells in a dose-dependent manner, while atializumab enhanced the number of regulatory T (Treg) cells. Furthermore, atializumab decreased not only splenic plasma cells and serum anti-dsDNA but also pathogenic IgG subclasses for nephritis. It suppressed NF-κB activation by inhibiting IκBα degradation in a dose-dependent manner in vitro. Atializumab alleviated nephritis by inhibiting autoreactive T, B, and plasma cells and decreasing NF-κB-related proinflammatory cytokines in lupus-prone mice. These results suggest that treatment targeting AIMP1 could be a novel and highly immune-modulating therapeutic strategy in lupus nephritis. | - |
dc.description.sponsorship | This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education ( 2017R1D1A1B03029050 ) and a faculty research grant of Yonsei University College of Medicine ( 6-2016-0159 ). Also, this study was conducted by a research project with the support of Handok ( HANDOK-2017-005 ). In addition, this research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) ( NRF-2017R1A2B4002968 ). | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Ltd | - |
dc.subject.mesh | Atializumab | - |
dc.subject.mesh | Cytokines | - |
dc.subject.mesh | Humanized antibody | - |
dc.subject.mesh | Lupus nephritis | - |
dc.subject.mesh | Lupus-prone mice | - |
dc.subject.mesh | Synthetases | - |
dc.subject.mesh | Animals | - |
dc.subject.mesh | Antibodies | - |
dc.subject.mesh | Antibody Affinity | - |
dc.subject.mesh | Antigen-Antibody Complex | - |
dc.subject.mesh | Cytokines | - |
dc.subject.mesh | DNA | - |
dc.subject.mesh | Humans | - |
dc.subject.mesh | Immunoglobulin G | - |
dc.subject.mesh | Intercellular Adhesion Molecule-1 | - |
dc.subject.mesh | Kidney | - |
dc.subject.mesh | Lupus Nephritis | - |
dc.subject.mesh | Lymphocyte Subsets | - |
dc.subject.mesh | Male | - |
dc.subject.mesh | Mice, Inbred C57BL | - |
dc.subject.mesh | Spleen | - |
dc.subject.mesh | Vascular Cell Adhesion Molecule-1 | - |
dc.title | Atializumab, a humanized anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) antibody significantly improves nephritis in (NZB/NZW) F1 mice | - |
dc.type | Article | - |
dc.citation.title | Biomaterials | - |
dc.citation.volume | 220 | - |
dc.identifier.bibliographicCitation | Biomaterials, Vol.220 | - |
dc.identifier.doi | 2-s2.0-85070076960 | - |
dc.identifier.pmid | 31394431 | - |
dc.identifier.scopusid | 2-s2.0-85070076960 | - |
dc.identifier.url | http://www.journals.elsevier.com/biomaterials/ | - |
dc.subject.keyword | Aminoacyl-tRNA synthetase (ARS)-interacting multifunctional protein 1 | - |
dc.subject.keyword | Atializumab | - |
dc.subject.keyword | Humanized antibody | - |
dc.subject.keyword | Inflammatory cytokine | - |
dc.subject.keyword | Lupus nephritis | - |
dc.subject.keyword | Lupus-prone mice | - |
dc.type.other | Article | - |
dc.identifier.pissn | 0142-9612 | - |
dc.description.isoa | false | - |
dc.subject.subarea | Biophysics | - |
dc.subject.subarea | Bioengineering | - |
dc.subject.subarea | Ceramics and Composites | - |
dc.subject.subarea | Biomaterials | - |
dc.subject.subarea | Mechanics of Materials | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.